Pollard has been in the healthcare industry for more than 15 years, initially as an equity analyst. He co-founded Abingdon Health in 2008 and was previously head of life science research at Numis. Pollard also spent time at Seymour-Pierce and Deutsche Bank and has a PhD in Molecular Virology and a BSc in Cell and Molecular Biology.
FTI said its life sciences arm has advised on 16 M&A deals since the start of 2014, worth more than $100bn (£65bn), and has advised on eight stock market flotations.
Ben Atwell, senior MD and head of FTI’s life sciences team, said: "We are very pleased that Brett is joining us and believe his deep experience from a range of different roles within the healthcare industry will benefit our clients and our established team of industry experts."
Pollard said: "I’ve worked with FTI as an analyst and as a client and believe that the team is the clear market leader in the life sciences sector in London. I am looking forward to helping strengthen and extend this leadership."